Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics, Inc. (STOK) is a clinical-stage biotechnology leader pioneering RNA-based medicines to address the root causes of severe genetic diseases. This page serves as the definitive source for official updates on therapeutic advancements, financial developments, and strategic initiatives related to their TANGO platform technology.
Investors and researchers will find curated press releases covering clinical trial progress, regulatory milestones, and peer-reviewed research on antisense oligonucleotide therapies. The repository includes updates on STOK's pipeline targeting central nervous system disorders and ocular conditions caused by haploinsufficiency.
Key content categories include treatment development timelines, partnership announcements with academic institutions, and financial performance reports. All materials maintain rigorous scientific accuracy while remaining accessible to both professional analysts and engaged public stakeholders.
Bookmark this page for direct access to Stoke Therapeutics' latest breakthroughs in RNA splicing modulation and protein restoration therapies. Regularly updated to reflect new developments in precision medicine innovation.
Stoke Therapeutics (Nasdaq: STOK) announced new preclinical data showing successful in-vitro protein upregulation and enhanced mitochondrial function in fibroblasts from ADOA patients. This data highlights the effectiveness of their TANGO approach in addressing the OPA1 protein deficiency, the primary cause of ADOA. With ADOA affecting approximately 1 in 30,000 people, the findings suggest a path toward disease-modifying treatment. Key results include a 35% to 47% increase in OPA1 protein isoform expression and improved mitochondrial bioenergetics.
Stoke Therapeutics (Nasdaq: STOK) announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized its Clinical Trial Application for a Phase 1/2a study (ADMIRAL) of STK-001, targeting Dravet syndrome. This proprietary antisense oligonucleotide aims to be the first disease-modifying therapy for this genetic epilepsy, which involves severe seizures and cognitive deficits. The study plans to enroll 22 patients across UK sites, with patient enrollment expected in the second half of 2021. STK-001 is currently in another trial (MONARCH) in the U.S., where initial dose cohorts are underway.
Stoke Therapeutics (Nasdaq: STOK) announced CEO Edward M. Kaye, M.D., will present at two investor conferences. The events include the Stifel 3rd Annual CNS Day on March 31, 2021, at 2:00 PM ET, and the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 12:45 PM ET. Both presentations will be available via live audio webcast on the company's investor site, with replays accessible for 30 days post-event. Stoke Therapeutics focuses on treating severe diseases through RNA-based medicines, including its lead compound STK-001 for Dravet syndrome.
Stoke Therapeutics (Nasdaq: STOK) reported a net loss of $52.3 million for 2020, equating to $1.56 per share, an increase from $32.3 million or $1.80 per share in 2019. R&D expenses rose to $32.2 million from $23.8 million, while G&A expenses surged to $20.8 million from $11.9 million. The Phase 1/2a MONARCH study for STK-001 in Dravet syndrome is progressing, with initial dosing completed. Stoke holds $287.5 million in cash to support operations into 2024, focusing on advancing RNA-based therapies.
Stoke Therapeutics (Nasdaq: STOK) announced that CEO Edward M. Kaye, M.D., will present at the Barclays Global Healthcare Conference on March 11, 2021, at 3:35 p.m. ET. The presentation will focus on the company's innovative RNA-based medicines designed to up-regulate protein expression and address severe diseases. A live audio webcast will be available on the Investors & Media section of Stoke’s website, with a replay accessible for 30 days post-presentation. Stoke’s lead candidate, STK-001, is aimed at treating Dravet syndrome, a severe genetic epilepsy.
Stoke Therapeutics (Nasdaq: STOK) announced that CEO Edward M. Kaye, M.D., will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 4:30 p.m. ET. The company specializes in addressing the underlying causes of genetic diseases by upregulating protein expression. A live audio webcast of the presentation will be available on Stoke’s Investors & Media page, with a replay accessible for 30 days post-event. Stoke aims to innovate treatment for autosomal dominant haploinsufficiencies, restoring essential protein levels for better health outcomes.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a pioneering biotechnology company, announced that CEO Edward M. Kaye, M.D., will participate in a fireside chat at the Needham Virtual Epilepsy & Pain – Specialty Therapeutics Conference on December 10, 2020, at 12:45 p.m. ET. The live audio webcast will be accessible on Stoke’s Investors & Media section of their website, with a replay available for 30 days. Stoke focuses on treating genetic diseases by upregulating protein expression, targeting autosomal dominant haploinsufficiencies to potentially restore health.
Stoke Therapeutics (Nasdaq: STOK) presented data at the 2020 American Epilepsy Society Annual Meeting regarding STK-001, a potential treatment for Dravet syndrome. Key findings include a baseline analysis from the BUTTERFLY study indicating significant cognitive impairments in children with Dravet, even when treated with existing therapies. The MONARCH study is underway to assess the safety and efficacy of STK-001. Preclinical data show promise in addressing the genetic cause of Dravet syndrome by potentially modifying disease progression and improving patient quality of life.
Stoke Therapeutics (Nasdaq: STOK) announced four abstracts on Dravet syndrome for the upcoming American Epilepsy Society 2020 Virtual Annual Meeting. Highlights include baseline data from the BUTTERFLY study evaluating neurodevelopmental status in children, details on the ongoing Phase 1/2a MONARCH study of STK-001, and new preclinical data supporting the efficacy of a TANGO antisense oligonucleotide. STK-001 aims to be a disease-modifying therapy addressing the genetic cause of Dravet syndrome, which affects around 35,000 individuals in select regions.
Stoke Therapeutics (Nasdaq: STOK) has successfully closed its public offering of 2,875,000 shares at $39.00 each, raising approximately $105.1 million in net proceeds. The offering included 375,000 shares from underwriters' option. Funds will support research, clinical development, and manufacturing for their product candidates, including STK-001 for Autosomal Dominant Optic Atrophy and other general corporate purposes. This offering was conducted under a previously filed SEC registration statement.
